

Notification of attendance and form for postal voting

The form must be received by Cinclus Pharma no later than 15 May 2026.

The shareholder below is hereby notifying the company of its participation and exercising the voting right for all of the shareholder's shares in Cinclus Pharma Holding AB (publ), Reg. No. 559136-8765 at the Annual General Meeting on 21 May 2026. The voting right is exercised in accordance with the voting options marked below.

Shareholder	Personal identity number/registration number

Assurance (if the undersigned is a legal representative of a shareholder who is a legal entity): I, the undersigned, am a board member, the CEO or a signatory of the shareholder and solemnly declare that I am authorized to submit this postal vote on behalf of the shareholder and that the contents of the postal vote correspond to the shareholder's decisions.

Assurance (if the undersigned represents the shareholder by proxy): The undersigned solemnly declare that the enclosed proxy corresponds to the original and has not been revoked.

Place and date	
Signature	
Clarification of signature	
Telephone number	E-mail

Instructions

- Complete all the requested information above.
- Select the preferred voting options below.
- Print, sign and send the form by post to Cinclus Pharma Holding AB (publ), Klarabergsviadukten 70, Elevator K, Floor 3, SE-111 64 Stockholm, Sweden or via e-mail to cincluspharma.generalmeetings@vinge.se.
- If the shareholder is a natural person who is personally voting in advance, it is the shareholder who should sign under *Signature* above. If the postal vote is submitted by a proxy of the shareholder, it is the proxy who should sign. If the postal vote is submitted by a legal representative of a legal entity, it is the representative who should sign.
- If the shareholder votes by proxy, a proxy shall be enclosed to the form. If the shareholder is a legal entity, a certificate of incorporation or an equivalent certificate of authority should be enclosed to the form.

A shareholder whose shares have been registered in the name of a bank or securities institute must register its shares in its own name to vote. Instructions for this is included in the notice convening the General Meeting.

A shareholder cannot give any other instructions than selecting one of the options specified at each item in the form. If a shareholder wishes to abstain from voting in relation to a matter, kindly refrain from selecting an option. A vote (i.e. the postal vote in its entirety) is invalid if the shareholder has provided the form with specific instructions or conditions or if pre-printed text is amended or supplemented.

The postal voting form, together with any enclosed authorization documentation, shall be provided to Cinclus Pharma no later than 15 May 2026. A postal vote can be withdrawn up to and including 15 May 2026 by contacting Cinclus Pharma via e-mail to cincluspharma.generalmeetings@vinge.se.

One form per shareholder will be considered. If more than one form is submitted, the form with the latest date will be considered. The form latest received by Cinclus Pharma will be considered if two forms are dated at the same date. An incomplete or wrongfully completed form may be discarded without being considered. If a shareholder has voted in advance and attends the Annual General Meeting in person or through a proxy, the postal vote is still valid except to the extent the shareholder participates in a voting procedure at the General Meeting or otherwise withdraws its casted postal vote. If the shareholder chooses to participate in a voting at the General Meeting, the vote cast will replace the postal vote with regard to the relevant item on the agenda.

Note that the postal vote does not constitute a notification to participate in the General Meeting at the venue in person or through proxy. Instructions for shareholders who wish to participate in the Annual General Meeting at the venue in person or represented by a proxy are included in the notice convening the Meeting.

For the complete proposals, kindly refer to the notice convening the General Meeting and the company's website www.cincluspharma.com/.

For information on how your personal data is processed, please refer to the Integrity Policy available on the Euroclear website; www.euroclear.com/dam/ESw/Legal/Privacy-notice-bolagsstammor-engelska.pdf.

Annual General Meeting in Cinclus Pharma Holding AB (publ) on 21 May 2026

The options below comprise the submitted proposals included in the notice convening the Annual General Meeting and are held available on the company's website.

2. Election of chairperson of the Annual General Meeting Yes <input type="checkbox"/> No <input type="checkbox"/>
4. Approval of the agenda Yes <input type="checkbox"/> No <input type="checkbox"/>
6. Determination of whether the Annual General Meeting has been duly convened Yes <input type="checkbox"/> No <input type="checkbox"/>
9. Resolution regarding adoption of the income statement and the balance sheet as well as the consolidated income statement and the consolidated balance sheet Yes <input type="checkbox"/> No <input type="checkbox"/>
10. Resolution regarding allocations of the company's result pursuant to the adopted balance sheet Yes <input type="checkbox"/> No <input type="checkbox"/>
11. Resolution regarding discharge from liability of the board members and the CEO
11.1 Lennart Hansson (<i>Chairman of the Board</i>) Yes <input type="checkbox"/> No <input type="checkbox"/>
11.2 Torbjörn Koivisto (<i>Board member</i>) Yes <input type="checkbox"/> No <input type="checkbox"/>
11.3 Helena Levander (<i>Board member</i>) Yes <input type="checkbox"/> No <input type="checkbox"/>
11.4 Nina Rawal (<i>Board member</i>) Yes <input type="checkbox"/> No <input type="checkbox"/>
11.5 Wenche Rolfsen (<i>Board member</i>) Yes <input type="checkbox"/> No <input type="checkbox"/>
11.6 Anders Öhberg (<i>Board member</i>) Yes <input type="checkbox"/> No <input type="checkbox"/>
11.7 Kjell Andersson (<i>Board member</i>) Yes <input type="checkbox"/> No <input type="checkbox"/>
11.8 Peter Unge (<i>Former Board member</i>) Yes <input type="checkbox"/> No <input type="checkbox"/>

<p>11.9 Christer Ahlberg (CEO)</p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>
<p>12a. Resolution regarding the number of board members</p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>
<p>12b. Resolution regarding the number of auditors</p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>
<p>13a. Resolution regarding the fees to the Board of Directors</p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>
<p>13b. Resolution regarding the fees to the auditor</p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>
<p>14. Election of board members</p>
<p>14a Lennart Hansson</p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>
<p>14b Wenche Rolfsen</p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>
<p>14c Torbjörn Koivisto</p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>
<p>14d Helena Levander</p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>
<p>14e Anders Lundström</p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>
<p>14f Fredrik Johansson</p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>
<p>14g David Armstrong</p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>
<p>15. Election of the chairperson of the Board of Directors Lennart Hansson</p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>
<p>16. Election of auditor</p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>
<p>17. Approval of the remuneration report</p> <p>Yes <input type="checkbox"/> No <input type="checkbox"/></p>

18. Resolution regarding authorization for the Board of Directors to resolve on new share issues Yes <input type="checkbox"/> No <input type="checkbox"/>
19. Resolution regarding long-term incentive program in the form of a performance share program (Performance Share Program 2026/2029), including:
19a. Adoption of the incentive program Yes <input type="checkbox"/> No <input type="checkbox"/>
19b. Authorization for the Board of Directors to resolve on a directed issue of class C shares, the repurchase of issued class C shares, the transfer of own ordinary shares to participants in the Performance Share Program 2026/2029 and in the market Yes <input type="checkbox"/> No <input type="checkbox"/>
19c. Resolution on share swap agreement with third party Yes <input type="checkbox"/> No <input type="checkbox"/>